Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Michael LoPresti"'
Autor:
Enxiang Zhang, Wenqi Cui, Michael Lopresti, Mara T. Mashek, Charles P. Najt, Hongbo Hu, Douglas G. Mashek
Publikováno v:
Journal of Lipid Research, Vol 61, Iss 3, Pp 338-350 (2020)
Lipid droplets (LDs) are energy-storage organelles that are coated with hundreds of proteins, including members of the perilipin (PLIN) family. PLIN5 is highly expressed in oxidative tissues, including the liver, and is thought to play a key role in
Externí odkaz:
https://doaj.org/article/081328d010024da1b05b34c5048f3ca2
Autor:
Akira Yuasa, Naohiro Yonemoto, Kazumasa Kamei, Toshiaki Murofushi, Michael LoPresti, Ankush Taneja, Jake Horgan, Shunya Ikeda
Publikováno v:
Advances in Therapy. 39:5327-5350
In light of the lack of an agreed international standard for how to conduct cost-effectiveness analyses (CEAs), including cost-utility analyses (CUAs) from a societal perspective, there is uncertainty regarding to what extent the inclusion of product
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d0830497ae1743ae7a0070a6a757784
https://doi.org/10.1007/s12325-022-02321-z
https://doi.org/10.1007/s12325-022-02321-z
Autor:
Atsuyuki Igarashi, Akira Yuasa, Naohiro Yonemoto, Kazumasa Kamei, Michael LoPresti, Toshiaki Murofushi, Shunya Ikeda
Publikováno v:
Dermatology and Therapy. 12:1729-1751
Psoriasis (PSO), atopic dermatitis (AD), and chronic urticaria (CU) are common manifestations of immunological skin and subcutaneous conditions and have been shown to have a substantial impact on the quality of life of patients. The cost of treating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce3f1ee505827b7aa1c79b2841093f49
https://doi.org/10.1007/s13555-022-00774-2
https://doi.org/10.1007/s13555-022-00774-2
Publikováno v:
Journal of Medical Economics. 25:552-560
This study aimed to ascertain the number of patients with chronic myelogenous leukemia (CML) and transplant-ineligible patients with multiple myeloma (MM) not recommended by their physicians for optimal drug treatment or who refuse, discontinue, redu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b51a0f43b9d7936c83c3f85f7bd0d9c2
https://doi.org/10.1080/13696998.2022.2062951
https://doi.org/10.1080/13696998.2022.2062951
Publikováno v:
Patient preference and adherence. 16
Manabu Akazawa,1 Daisuke Shima,2 Takahiro Sato,2 Emi Shoji,2 Michael LoPresti,3 Ryosuke Nishi3 1Department of Public Health and Epidemiology, Meiji Pharmaceutical University, Tokyo, Japan; 2Medical Affairs, Rare Disease, Pfizer Japan Inc, Tokyo, Japa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f87d08e2def9f8e52cec3b26cca77ad
https://pubmed.ncbi.nlm.nih.gov/36387049
https://pubmed.ncbi.nlm.nih.gov/36387049
Publikováno v:
Pharmacoeconomics
Background Inclusion of productivity losses and gains in cost-effectiveness analyses for drugs is recommended by pharmacoeconomic guidelines in some countries and is considered optional in others. Often guidelines recommend analysis based on the paye
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd0bb4121eb4dc0459e36487ab998af0
https://doi.org/10.1007/s40273-020-00986-4
https://doi.org/10.1007/s40273-020-00986-4
Introduction: The kinds of costs included in cost-effectiveness analyses (CEAs) for vaccines, such as direct medical costs and indirect costs, may affect their outcomes. While some guidelines recommend inclusion of costs associated with productivity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d22b22a4fe283c8959b08502866dcab4
Autor:
Michael Lopresti, Ines Guerra, Wentao Tang, Lucile Marié, Ataru Igarashi, Sandrine Cure, Kiichiro Tsutani
Publikováno v:
Current Medical Research and Opinion. 33:1-10
Objective: Across Japan, around 2 million people are infected with hepatitis C virus (HCV) with long-term complications such as cirrhosis, hepatocellular carcinoma (HCC) and liver transplant (LT). Current treatment options have several limitations du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4614d4819d4f2eabb667a7a9de14e29
https://doi.org/10.1080/03007995.2016.1222512
https://doi.org/10.1080/03007995.2016.1222512
Objective: Hepatitis C is the result of a ribonucleic acid (RNA) virus (hepatitis C virus; HCV). The Japan Society of Hepatology (JSH) estimated that 1.5–2 million people in Japan carry HCV. Six major HCV genotypes (GT) and a large number of subtyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4a112921c14002abb61d5cbdafc5372